January 3, 2023 7:35 pm Published by admin Happy New Year! With the new year, the Chondrosarcoma Foundation is kicking-off the year by hosting and promoting Chondrosarcoma Awareness Day on February 6 (Shayna’s heavenly 32nd birthday). We ask that you join us in wearing a Yellow Ribbon or a yellow wrist band and post pictures wearing Yellow on social media platforms at #cswecare [...]
December 26, 2022 4:43 pm Published by admin I would like to wish everyone the best for this holiday season. May you all cherish the moments you have with your family and blessings to you all for a Healthy and Happy New Year. I thank each and every one of you for the caring and support you have shown each other this past [...]
December 17, 2022 6:01 pm Published by admin With Chondrosarcoma Awareness Day: February 6, less than two months away, we want to share stories of our community / our family who provide us with inspiration. Some of our members lost their battle with Chondrosarcoma. Others are surviving, leading productive lives with the help of surgery, radiation, orphan medications and clinical trials. Our first [...]
December 10, 2022 5:38 pm Published by admin International Chondrosarcoma Awareness Day February 6, 2023 Wear A Yellow Ribbon / Wrist Band and Show Your Support for Chondrosarcoma Research and Clinical Trials As many of you are aware to honor my daughter who passed away from Grade 3 Conventional Chondrosarcoma; we started the Chondrosarcoma Foundation. We also dedicated February 6 (Shayna’s Birthday) as [...]
November 28, 2022 5:40 pm Published by admin Inhibrx has initiated a phase 2 clinical trial to treat unresectable or metastatic conventional chondrosarcoma. The poster was presented at the Connective Tissue Oncology Society (CTOS) in Vancouver, Canada from November 16-19. The results of the phase 1 study indicated stable or reduced metastatic chondrosarcoma from the DR5 antagonist, the agent known as a death [...]
November 23, 2022 5:49 pm Published by admin Inhibrx is recruiting for Chondrosarcoma patients to participate in their Phase 2 study of the medication. Presently there are 130 openings for the Phase 2 trial. Summary is listed below, for more details: https://clinicaltrials.gov/ct2/show/NCT04950075?cond=Chondrosarcoma&draw=2&rank=6 Study of INBRX-109 in Conventional Chondrosarcoma ClinicalTrials.gov Identifier: NCT04950075 Recruitment Status : Recruiting First Posted : July 6, 2021 Last Update [...]
October 25, 2022 4:20 pm Published by admin Background Central conventional chondrosarcoma (CS) is the most common primary malignant bone tumour in adults. Anatomical location, histopathology, and grading are the current criteria for determining treatment [1, 2], although providing prognoses remains challenging [1–3]; hence, a greater understanding of the disease, and its biomarkers is required to provide patients with a more personalized treatment [...]
October 24, 2022 4:39 pm Published by admin SAN DIEGO, Oct. 20, 2022 /PRNewswire/ — Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced it will be presenting at multiple upcoming scientific conferences. American Conference on Pharmacometrics (ACoP)13th Annual Meeting October 30th – November 2nd, 2022 – Aurora, Colorado Title: PK/PD [...]
October 21, 2022 5:00 pm Published by admin Here are pictures from our event: Steppin’ for A Cause held on October 15, at Allen Pond in Bowie, Maryland. We had 50 people participate in our 5k Walk / Run and raised $3,200 ($500 more than last year). Thank you to everyone for your support.
